Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-432 adjuvant selpercatinib in RET fusion-positive NSCLC
NL-OMON58827Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Selpercatinib with Placebo (2 arms). Primary endpoint: Event-free survival. Started Mar 2022; status: active, not recruiting.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON58827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58827.